IBRX vs PHM · rev $113.3M vs P/E 7.7, rev $17.95B
Immunitybio Inc (IBRX) versus PulteGroup Inc (PHM) — a side-by-side from cached financials, not a winner call.
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
PulteGroup Inc (PHM) is a residential construction company listed on US.
Latest reported IBRX revenue for 2025-12-31 was $113.3M. Net income was -$351.4M. Revenue was up 668.3% from 2024-12-31 to 2025-12-31. IBRX currently screens at market cap $7.88B.
Latest reported PHM revenue for 2024-12-31 was $17.95B. Net income was $3.08B. Revenue was up 11.7% from 2023-12-31 to 2024-12-31. PHM currently screens at market cap $21.92B and trailing P/E 7.7.
IBRX currently screens at market cap $7.88B. PHM currently screens at market cap $21.92B and trailing P/E 7.7.
Not investment advice. Open the IBRX and PHM stock pages for the full models.
Not investment advice.